Calytrix Bio was founded in 2025 with a mission to transform the lives of patients living with myeloproliferative neoplasms (MPNs). Patients with these complex, progressive blood cancers have long hoped for truly disease-modifying therapies. At Calytrix Bio, we aspire to “change the course by going to the source.” We aim to deliver new therapeutic options, leveraging deep engagement with the MPN community and nimble development execution.
| Employees | 8 (8 on RocketReach) |
| Founded | 2025 |
| Industry | Biotechnology Research |
Looking for a particular Calytrix Bio employee's phone or email?
Brad Prosek is the President and CEO of Calytrix Bio.
8 people are employed at Calytrix Bio.